Research
Hormonal
Short-term intensive insulin therapy can induce T2DM remission in newly diagnosed patients with high blood glucose levels (HbA1c ≥ 10% and FBG ≥ 11.1 mmol/L) by restoring beta-cell function.
If you were just diagnosed with Type 2 Diabetes and your blood sugar is very high, your doctor might suggest a short course of insulin. This isn't forever; it's used to quickly lower your blood sugar and give your pancreas a break so it can start working better on its own. This is most effective for people recently diagnosed.
LimitedConditionalMEDIUM confidence
Recommendation 8: Adjunctive short-term (2-week) early insulin intensive therapy for patients with HbA1c ≥ 10% and FBG ≥ 11.1 mmol/L can assist in inducing remission of T2DM (Evidence Level Moderate (2a), Recommendation Level: B).
Why this rating
Rated 'Moderate (2a)' evidence and 'Weak (B)' recommendation.
Source
Expert Consensus on Type 2 Diabetes Remission
Exploration of Endocrine and Metabolic Diseases · 2026
DOI 10.37349/eemd.2026.101473
clinical_guideline
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intensive lifestyle interventions, specifically achieving significant weight loss (≥10-15 kg or ≥10% body weight), can induce Type 2 Diabetes (T2DM) remission in overweight or obese patients by correcting insulin resistance and restoring beta-cell function.Weak
- Metabolic surgery (bariatric surgery) is a highly effective treatment for T2DM remission in patients with BMI ≥ 32.5 kg/m2, offering higher remission rates and long-term benefits compared to conventional treatments.Weak
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →